Welcome to BioSeeker Group!

Cancer Vaccines Fantasy or Future?

Additional Information

Published Date Feb 1, 2005
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 175
PDF Fact Sheet View Fact Sheet for the report Cancer Vaccines Fantasy or Future? in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

In this newly updated progress analysis, BioSeeker not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Cancer Vaccines Fantasy or Future?.

    To find out more about Cancer Vaccines Fantasy or Future?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Cancer Vaccines Fantasy or Future? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Executive Summary

The concept of utilizing the immune system for the treatment of cancer has been tried for some time without any direct breakthrough success. So far "passive" immunotherapy has experienced most success, with antibody and cytokine therapy leading the way.

An example of difficulties and risks associated with this field is shown by Dendreon’s latest failure, in January 2005 of their late stage cancer vaccine candidate Provenge. The new and updated progress analysis report "Cancer Vaccines Fantasy or Future" by BioSeeker Group continues to provide the latest information and analysis on industry related as well as important academic activities.

Active immunotherapy strategies have emerged and progress in the molecular characterization of human tumors and a better understanding of tumor immunology has resulted in the discovery of tumor-associated antigens (TAAs). TAA-based vaccines are at present being evaluated. It is broadly admitted that therapeutic vaccines will initially and in the near future be efficient only on a limited tumor burden. Cancer vaccines ought to be used in an adjuvant setting, for instance in order to remove residual disease after surgical treatment of the tumor. As well, in light of the fact that some of these experimental vaccines can elicit immune and clinical responses even in patients with advanced cancer, cancer vaccines can also be considered for slowing down disease progression and conserve quality of life.

BioSeeker Group has since several years continuously studied the progress in cancer immunotherapy strategies. In this newly updated progress analysis we not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements.

Reasons Why You Should Read This Report:

  • Get a solid background of what is happening in the Cancer Vaccine field.
  • Learn how the strategies have improved.
  • Make sure that you have the latest information about the most prominent Cancer Vaccine candidates.
  • Speed up your R&D by finding collaborators or partners.

Methodology

Introduction to cancer immunotherapy

Improved strategies

Progress analysis on cancer vaccine candidates:

Actimmune

Allovectin-7

Avicine

BEC2

Canvaxin

CeaVac

CaPVax. (DCVax).

Gastrimmune

GMK

LymphoCide

Melacine

M-Vax

MyVax

Oncophage

OncoVAX

Osidem

Ovarex

Provenge

Theratope

TroVax

Company Profiles

Appendix: Progress profiles on therapeutic candidates

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Cancer Vaccines Fantasy or Future?.
    To find out more about Cancer Vaccines Fantasy or Future?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Cancer Vaccines Fantasy or Future? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
This report will excel your competitive awareness and decrease your decision making time in managing apoptotic drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you. Learn More


Antibody Drug Target Atlas in Oncology
First of its kind, "Antibody Drug Target Atlas in Oncology" provides a comprehensive analysis of the commercialization of antibody drug targets in oncology Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Melanoma and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Melanoma and Pancreatic Cancer. Learn More


Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Peptides
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors and by the compound strategy of Peptides. Learn More

Other selected research from the 'Vaccines' category:


Cancer Vaccines Drug Pipeline Update
BioSeeker Group have identified 314 companies plus partners who are today developing 386 cancer vaccine drugs in 784 developmental projects in cancer across 195 different targets. In addition, there are 8 suspended drugs and another 208 drugs where development has been ceased. Learn More


Cancer Vaccines: Analytical Tool
This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of cancer vaccines. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More